Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

Objectives This study aimed to investigate serum glutathione reductase (GR) levels in patients with SLE and to assess its association with disease activity.Methods The retrospective study collected ...

To explore the impact of identified predictors, subgroup analyses showed a higher proportion of patients with acute flare without low C3/C4 (n=10) achieved BICLA response at Week 24 vs patients with ...

ARTICLES. Levels of complement C3 and C4 components in Amerindians living in an area with high prevalence of tuberculosis . Zaida Araujo I, 1; Nieves González II; Laura de Cubeddu II; Rita C Ziegler ...

Background/objectives The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus system showed high specificity ...

2025 has turned out to be a disappointing year for C3.ai (AI-2.17%) investors so far. Shares of the enterprise artificial intelligence (AI) software provider trade down about 29% so far as of this ...

C3.ai, Inc. (NYSE:AI) is an enterprise artificial intelligence (AI) software company involved in building and operating enterprise-scale AI applications and accelerating digital transformation.

Data by YCharts.. Of course, there is a good chance that C3.ai could do better and outpace Wall Street's growth expectations in the future. But even if its top line jumps to $696 million in fiscal ...

C3.ai does not have an earnings ratio due to its lack of profitability, but it does trade at a high price-to-sales ratio of 8.3 as of this writing on June 11, 2025.

CoreWeave and C3.ai are showing resilience amid macroeconomic uncertainty. CoreWeave's revenues rose 420% in Q1 as a wave of hyperscalers sought more AI computing power. Two examples of this are ...